No evidence that anti-inflammatory treatment prevents progression to T2DM in CANTOS trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Brendan Everett, MD - Boston, MA, USA

ACC 2018 Due to the observed link between inflammation and aberrant insulin regulation, a key secondary outcomes of the CANTOS trial was new onset T2DM in patients with prediabetes at baseline.

Educational information

This 3-minute education provides a summary of just presented scientific data, recorded during the ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.

Faculty

Brendan Everrett, MD is a cardiologist at Brigham and Women's Hospital, Boston, MA, USA

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Listen to Brendan Everett discussing the diabetes results of the CANTOS trial

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.